A H V Remels

Summary

Affiliation: Maastricht University
Country: The Netherlands

Publications

  1. request reprint
    Remels A, Schrauwen P, Broekhuizen R, Willems J, Kersten S, Gosker H, et al. Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J. 2007;30:245-52 pubmed
    ..Therefore, a disturbed expression of these regulatory factors may well underlie the disturbed skeletal muscle functioning in chronic obstructive pulmonary disease. ..
  2. Remels A, Gosker H, Schrauwen P, Langen R, Schols A. Peroxisome proliferator-activated receptors: a therapeutic target in COPD?. Eur Respir J. 2008;31:502-8 pubmed publisher
    ..Proposed mechanisms will be outlined in the present article, as well as the therapeutic potential of peroxisome proliferator-activated receptor modulation in the treatment of skeletal muscle dysfunction. ..
  3. Remels A, Langen R, Schrauwen P, Schaart G, Schols A, Gosker H. Regulation of mitochondrial biogenesis during myogenesis. Mol Cell Endocrinol. 2010;315:113-20 pubmed publisher
    ..In particular, PGC-1alpha and PPAR-alpha may be involved in the regulation of mitochondrial biogenesis during myogenesis. ..
  4. Remels A, Langen R, Gosker H, Russell A, Spaapen F, Voncken J, et al. PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am J Physiol Endocrinol Metab. 2009;297:E174-83 pubmed publisher
    ..These findings demonstrate that muscle-specific inhibition of NF-kappaB activation may be an interesting therapeutic avenue for treatment of several inflammation-associated skeletal muscle abnormalities. ..

Detail Information

Publications4

  1. request reprint
    Remels A, Schrauwen P, Broekhuizen R, Willems J, Kersten S, Gosker H, et al. Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J. 2007;30:245-52 pubmed
    ..Therefore, a disturbed expression of these regulatory factors may well underlie the disturbed skeletal muscle functioning in chronic obstructive pulmonary disease. ..
  2. Remels A, Gosker H, Schrauwen P, Langen R, Schols A. Peroxisome proliferator-activated receptors: a therapeutic target in COPD?. Eur Respir J. 2008;31:502-8 pubmed publisher
    ..Proposed mechanisms will be outlined in the present article, as well as the therapeutic potential of peroxisome proliferator-activated receptor modulation in the treatment of skeletal muscle dysfunction. ..
  3. Remels A, Langen R, Schrauwen P, Schaart G, Schols A, Gosker H. Regulation of mitochondrial biogenesis during myogenesis. Mol Cell Endocrinol. 2010;315:113-20 pubmed publisher
    ..In particular, PGC-1alpha and PPAR-alpha may be involved in the regulation of mitochondrial biogenesis during myogenesis. ..
  4. Remels A, Langen R, Gosker H, Russell A, Spaapen F, Voncken J, et al. PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am J Physiol Endocrinol Metab. 2009;297:E174-83 pubmed publisher
    ..These findings demonstrate that muscle-specific inhibition of NF-kappaB activation may be an interesting therapeutic avenue for treatment of several inflammation-associated skeletal muscle abnormalities. ..